

BÖLÜM 9

İmmün Trombositopeni

Esra TURAN ERKEK¹

Giriş

İmmün trombositopeni (İTP), çocuklar ve erişkinlerde görülen izole trombositopeni ile karakterize edinsel, otoimmün bir hastalıktır. Günümüzde “İTP” kısaltması kullanılmaya devam etse de, önceki “idiyopatik” tanımının yerini ‘immün’ almıştır. Ek olarak bir çok hastada kanama bulgusu saptanmadığından ‘purpura’ kullanılmamakta; güncel olarak hastalık immün trombositopeni (İTP) olarak hastalık tanımlanmaktadır (1).

İmmün trombositopenik hastalar, trombosit sayısının $<100 \times 10^9/L$ laboratuvar bulgusu ve asemptomatik veya hafif mükokutanöz kanamadan yaşamı tehdit edici kanamalara değişen kanama bulguları ile başvurabilir (2). Hastaların sadece %5’i hemodinamik instabilite yaratacak yada intrakranial, intraspinal, intraoküler, retroperitoneal, perikardiak bölge gibi hayatı tehdit edecek bölgelerde kanama ile başvurarak ‘**ağır İTP**’ olarak tanı almaktadır (3).

Klinik bulgu olarak hastalar değişen kanama bulguları yanında, kanama bulgularının derecesinden bağımsız olarak, yorgunluk ve yaşam kalitesinde azalma bildirmektedirler (4).

Terminoloji

İmmün trombositopeninin spesifik bir tanı belirteci veya kriteri yoktur; bir dışlama tanısıdır: altta yatan bir neden olmadan, izole trombositopeni gelişimi ‘**primer İTP**’, diğer hastalıklar veya tedaviler tarafından indüklenen

¹ Uzm. Dr., Kartal Dr. Lütfi Kırdar Şehir Hastanesi, Erişkin Hematoloji Yan Dal Uzmanı, dresaturan@gmail.com

Kaynaklar

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. *Blood*. 2009;113(11):2386-2393.
2. Cooper N, Ghanima W. Immune Thrombocytopenia. *N Engl J Med*. 2019 Sep 5;381(10):945-955. doi: 10.1056/NEJMcp1810479. PMID: 31483965.
3. Piel-Julian ML, Mahévas M, Germain J, et al. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. *J Thromb Haemost* 2018; 16: 1830-42.
4. Efficace F, Mandelli F, Fazi P, et al. Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. *Am J Hematol*. 2016 Oct;91(10):995-1001. doi: 10.1002/ajh.24463. Epub 2016 Jul 14. PMID: 27351715.
5. Moulis G, Palmaro A, Montastruc JL, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. *Blood*. 2014 Nov 20;124(22):3308-15. doi: 10.1182/blood-2014-05-578336. Epub 2014 Oct 10. PMID: 25305203.
6. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv*. 2019 Dec 10;3(23):3829-3866. doi: 10.1182/bloodadvances.2019000966. Erratum in: *Blood Adv*. 2020 Jan 28;4(2):252. PMID: 31794604; PMCID: PMC6963252.
7. Bennett CM, Neunert C, Grace RF, et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. *Pediatr Blood Cancer*. 2018 Jan;65(1). doi: 10.1002/pbc.26736. Epub 2017 Aug 9. PMID: 28792679.
8. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. *Blood*. 1999 Aug 1;94(3):909-13. PMID: 10419881.
9. Stegner D, vanEeuwijk JMM, Angay O, et al. Thrombopoiesis is spatially regulated by the bone marrow vasculature. *Nat Commun*. 2017 Jul 25;8(1):127. doi: 10.1038/s41467-017-00201-7. PMID: 28743899; PMCID: PMC5527048.
10. Grozovsky R, Begonja AJ, Liu K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. *Nat Med*. 2015 Jan;21(1):47-54. doi: 10.1038/nm.3770. Epub 2014 Dec 8. PMID: 25485912; PMCID: PMC4303234.
11. Swinkels M, Rijkers M, Voorberg J, et al. Emerging Concepts in Immune Thrombocytopenia. *Front Immunol*. 2018 Apr 30;9:880. doi: 10.3389/fimmu.2018.00880. PMID: 29760702; PMCID: PMC5937051.
12. Audia S, Santegoets K, Laarhoven AG, et al. Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia. *Clin Exp Immunol*. 2017;188(2):275-282.
13. Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. *J Thromb Haemost*. 2009;7(2):322-329.
14. Mahevas M, Patin P, Huetz F, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. *J Clin Invest*. 2013;123(1):432-442.
15. Kuwana M, Kawakami Y, Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/ CD154 interaction: implications for treatment of immune thrombocytopenic purpura. *Blood*. 2003;101(2):621-623.
16. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. *Blood*. 2003 Aug 1;102(3):887-95. doi: 10.1182/blood-2002-05-1475. Epub 2003 Apr 3. PMID: 12676790.
17. Lev PR, Grodzielski M, Goette NP, Glembofsky AC, Espasandin YR, Pierdominici MS,

- Conrufo G, Montero VS, Ferrari L, Molinas FC, Heller PG, Marta RF. Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count. *Br J Haematol*. 2014 Jun;165(6):854-64. doi: 10.1111/bjh.12832. Epub 2014 Mar 27. PMID: 24673454.
18. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood* 2010;115: 168-86.
 19. Khellaf M, Michel M, Schaeffer A, et al. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. *Haematologica* 2005; 90:829-32.
 20. Adelborg K, Kristensen NR, Nørgaard M, et al. Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia. *J Thromb Haemost* 2019; 17:912-24.
 21. Mizutani H, Furubayashi T, Imai Y, et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW x BXSb) F1. *Blood*. 1992 Feb 15;79(4):942-7. PMID: 1737103.
 22. Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. *Lancet Haematol*. 2016 Oct;3(10):e489-e496. doi: 10.1016/S2352-3026(16)30109-0. Epub 2016 Sep 16. PMID: 27658982.
 23. Frederiksen H, Ghanima W. Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia. *Eur J Intern Med*. 2017 Jan;37:e23-e25. doi: 10.1016/j.ejim.2016.09.001. Epub 2016 Sep 12. PMID: 27633568.
 24. Ghanima W, Godeau B, Cines DB, et al. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. *Blood*. 2012 Aug 2;120(5):960-9. doi: 10.1182/blood-2011-12-309153. Epub 2012 Jun 26. PMID: 22740443.
 25. Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. *N Engl J Med*. 2011 Aug 25;365(8):734-41. doi: 10.1056/NEJMct1014202. PMID: 21864167.
 26. Erickson-Miller CL, Delorme E, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. *Stem Cells*. 2009 Feb;27(2):424-30. doi: 10.1634/stemcells.2008-0366. PMID: 19038790; PMCID: PMC2729672.
 27. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. *Cytokine*. 2004 Jan 21;25(2):52-60. doi: 10.1016/j.cyto.2003.05.001. PMID: 14693160.
 28. D'Areola G, Guariglia R, Mansueto G, et al. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. *Blood*. 2013 Feb 14;121(7):1240-2. doi: 10.1182/blood-2012-11-465575. Erratum in: *Blood*. 2014 Mar 20;123(12):1971. Dosage error in article text. PMID: 23411736.
 29. Wang L, Gao Z, Chen XP, Zhang HY, et al. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis. *Sci Rep*. 2016 Dec 19;6:39003. doi: 10.1038/srep39003. PMID: 27991534; PMCID: PMC5171907.
 30. Khellaf M, Viallard JF, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. *Haematologica*. 2013 Jun;98(6):881-7. doi: 10.3324/haematol.2012.074633. Epub 2013 Feb 26. PMID: 23445876; PMCID: PMC3669443.
 31. Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. *Br J Haematol*. 2016 Jan;172(2):262-73. doi: 10.1111/bjh.13827. Epub 2015 Nov 5. PMID: 26537623.
 32. González-López TJ, Pascual C, Álvarez-Román MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.

- nia. *Am J Hematol* 2015;90(3): E40-E43. doi: 10.1002/ajh.23900. Epub 2015 Jan 16. PMID: 25400215.
33. Deshayes S, Khellaf M, Zarour A, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. *Am J Hematol*. 2019 Dec;94(12):1314-1324. doi: 10.1002/ajh.25632. Epub 2019 Oct 8. PMID: 31489694.
 34. Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet*. 2015;385(9978):1653-1661. [https://doi.org/10.1016/S0140-6736\(14\)61495-1](https://doi.org/10.1016/S0140-6736(14)61495-1).
 35. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. *Blood*. 2012;119(25):5989-5995. <https://doi.org/10.1182/blood-2011-11-393975>.
 36. Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? *Haematologica* 2019; 104: 1124-35.
 37. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. *Am J Hematol*. 2018;93(7):921-930
 38. Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. *Blood*. 2004;104(9):2623-2634.
 39. Palandri F, Polverelli N, Sollazzo D, et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. *Am J Hematol*. 2016;91(4):E267-E272.
 40. Gwilliam NR, Lazar DA, Brandt ML, et al. An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura. *J Pediatr Surg*. 2012;47(8):1537-1541.
 41. Gonzalez-Porrás JR, Escalante F, Pardo E, et al; Grupo de Trombosis y Hemostasia de Castilla y León. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. *Eur J Haematol*. 2013;91(3):236-241.
 42. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. *Blood*. 2004;104(4):956-960.
 43. Kim M, Park KM, Shin WY, et al. Platelet count evolution as a predictor of outcome after splenectomy for immune thrombocytopenic purpura. *Int J Hematol*. 2017;105(4):433-439.
 44. Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. *Blood*. 2018 Mar 15;131(11):1172-1182. doi: 10.1182/blood-2017-09-742353. Epub 2018 Jan 2. PMID: 29295846; PMCID: PMC5855018.
 45. Vishwekar PS, Yadav RK, Gohel CB. Thrombocytopenia during pregnancy and its outcome – a prospective study. *J Krishna Inst Medical Sciences Univ* 2017;6:82–89.
 46. Cines DB, Blanchette VS, Chir B. Immune thrombocytopenic purpura. *N Engl J Med* 2002;346:995–1008. doi: 10.1056/NEJMra010501.
 47. Reese JA, Deschamps DR, McIntosh JJ, et al. Platelet counts throughout uncomplicated pregnancies. *Blood* 2015;126:2256.
 48. Eslick R, McLintock C. Managing ITP and thrombocytopenia in pregnancy. *Platelets*. 2020;31(3):300-306. doi: 10.1080/09537104.2019.1640870. Epub 2019 Jul 11. PMID: 31296105.
 49. Sun D, Shehata N, Xiang YY, et al. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. *Blood* 2016;128:1329–1335. doi: 10.1182/blood-2016-04-710285.
 50. British Committee for Standards in Haematology. Guidelines for the investigation and ma-

- nagement of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. *Br J Haematol* 2013;120:574–596.
51. Rajasekhar A, Gernsheimer T, Stasi R, James AH. 2013 Clinical practice guide on thrombocytopenia in pregnancy. Washington, DC: American Society of Hematology;2013 Available from. <http://www.hematology.org/Clinicians/Guidelines-Quality/Quick-Reference.aspx>.
 52. Schmid J, Piroth D, Buhrlen M, et al. Successful rituximab treatment of refractory immune thrombocytopenia during pregnancy. *Onkologie* 2011;34:240.
 53. Pavanello F, Zucca E, Ghielmini M. Rituximab: 13 open questions after 20 years of clinical use. *Cancer Treat Rev* 2017;53:38–46. doi: 10.1016/j.ctrv.2016.11.015.
 54. Griffiths J, Sia W, Shapiro AM, et al. Laparoscopic splenectomy for the treatment of refractory immune thrombocytopenia in pregnancy. *J Obstet Gynaecol Can* 2005;27:771–774.
 55. Mahey R, Kaur SD, Chumber S, et al. Splenectomy during pregnancy: treatment of refractory immune thrombocytopenic purpura. *BMJ Case Rep* 2013. Published online: 19 December 2018. doi: 10.1136/bcr-2013-201778.
 56. Care A, Pavord S, Knight M, et al. Severe primary autoimmune thrombocytopenia in pregnancy: a national cohort study. *Br J Obstet Gynaecol* 2018;125:604–612. doi: 10.1111/1471-0528.14697.
 57. Combs CA, Murphy EL, Laros JRK. Factors associated with postpartum haemorrhage with vaginal birth. *Obstet Gynecol* 1991;77:69–76.
 58. Kawaguchi K, Matsubara K, Takafuta T, et al. Factors predictive of neonatal thrombocytopenia in pregnant women with immune thrombocytopenia. *Int J Hematol* 2014;99:570–576. doi: 10.1007/s12185-014-1562-6.
 59. Practice Bulletin ACOG. No 207: thrombocytopenia in pregnancy. *Obstet Gynecol* 2019;133:e181–193. doi: 10.1097/AOG.00000 00000003100.